Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Expanded Access

Expanded Access

                        Expanded Access | Information for Patients
          Expanded Access | Information for Physicians
          Expanded Access | Information for Industry
          Expanded Access | How to Submit a Request (Forms)
          Expanded Access | Keywords, Definitions, and Resources
          Expanded Access (Compassionate Use) Submission Data
          FDA's Expanded Access Contact Information Home
          News & Events
          Public Health Focus
          Expanded Access
          Expanded Access Categories for Drugs (Including Biologics)Expanded Access Expanded Access Categories for Drugs (Including Biologics)
  
  	
    Share
    Post
    Linkedin

    Email
    PrintFor each of the three expanded access categories, there are two types of regulatory submissions that can be used: a new investigational new drug application (IND) or a protocol (treatment plan) submitted as a protocol amendment to an existing IND.

Individual Patient Access

**Individual Patient Expanded Access IND (also referred to as a Single Patient IND):**

Access to an investigational drug (including a biologic) for use by a single patient submitted as a protocol *under a new IND*. The investigational product may or may not be under development. Unless FDA notifies the sponsor that treatment may begin earlier, there is a 30-day waiting period before treatment with the drug may begin.

**Individual Patient Expanded Access Protocol (also referred to as a Single Patient Protocol):**

Access to an investigational drug (including a biologic) for use by a single patient submitted as a new protocol *to an existing IND by the sponsor of the existing IND*.  Typically, several patients may follow the same protocol. The investigational product may or may not be under development. There is no 30- day waiting period before treatment with the investigational product may begin, but the protocol must be received by FDA and have approval by an Institutional Review Board (IRB) before treatment may begin.

**Individual Patient Access in an Emergency (also known as emergency expanded access use and emergency access):****

*Please note that Emergency INDs and protocols are a subset of Individual Patient Access.*

**(1) Emergency IND:**Individual Patient Access IND for Emergency use: Access to an investigational drug (including a biologic) for use by a single patient in an emergency situation (i.e., a situation that requires a patient to be treated before a written submission can be made) submitted as a protocol *under a new IND*. Treatment is initially requested and authorized by telephone or other rapid means of electronic communication, and may start immediately upon FDA authorization. The written submission (i.e., the individual patient expanded access IND) must be submitted within 15 business days of the telephone authorization.

**(2) Emergency Protocol:** Individual Patient Expanded Access Protocol for Emergency Use: Access to an investigational drug (including a biologic) for use by a single patient in an emergency situation (i.e., a situation that requires a patient to be treated before a written submission can be made) submitted as a new protocol *to an existing IND by the sponsor of the existing IND*. Treatment is initially requested and authorized by telephone or other rapid means of communication, and treatment may start immediately upon FDA authorization. The written submission (i.e., the individual patient expanded access protocol) must be submitted within 15 business days of the telephone authorization.

In an emergency situation where there is not sufficient time to secure IRB review prior to beginning treatment, the emergency use of the investigational drug must be reported to the IRB within 5 working days, as required under 21 CFR 56.104(c).

More Information for Submitting an Emergency Request

Intermediate-Size Patient Population Access

**Intermediate-size Patient Population Expanded Access IND:**

Access to an investigational drug (including a biologic) for use by more than one patient, but generally fewer patients than are treated under a typical treatment IND or protocol, submitted as a protocol *under a new IND*. The investigational product may or may not be under development for marketing. Unless FDA notifies the sponsor that treatment may begin earlier, there is a 30-day waiting period before treatment may begin.

**Intermediate-size Patient Population Expanded Access Protocol:**

Access to an investigational drug (including a biologic) for use by more than one patient, but generally fewer patients than are treated under a typical treatment IND or protocol, submitted as a protocol *to an existing IND by the sponsor of the existing IND*. The investigational product may or may not be under development for marketing. There is no 30-day waiting period before treatment with the investigational product may begin, but the protocol must be received by FDA and have IRB approval before treatment may begin.

An intermediate-size patient population protocol may also be requested to allow access to treatment with an approved drug (including a biologic) or a related product that is not available through marketing channels because of failure to meet the conditions of approval or a drug shortage, provided the drug and the patient meet the general criteria for expanded access as well as the criteria specific to use in an intermediate-size patient population.

Expanded Access for Widespread Use

**Treatment IND:**

Access to an investigational drug (including a biologic) for treatment use by a large (widespread) population, submitted as a protocol *under a new IND*. The investigational product must be under active development for marketing. Unless FDA notifies the sponsor that treatment may begin earlier, there is a 30-day waiting period before treatment may begin.

**Treatment Protocol:**

Access to an investigational drug (including a biologic) for treatment use by a large (widespread) population, submitted as a protocol *to an existing IND by the sponsor of the existing IND*. The investigational product must be under development for marketing. Unlike other access protocols submitted to existing INDs, there is a 30-day waiting period before treatment may begin, unless FDA notifies the sponsor that treatment may begin earlier.

Visit the Expanded Access (Compassionate Use) Main Page

Related Information

21 CFR part 312 subpart I
	FDA's Final Guidance: Expanded Access to Investigational Drugs for Treatment Use—Questions
	Expanded Access: Criteria for an Investigational Product to be Made Available For Widespread Use Under a Treatment Protocol or Treatment IND/ Treatment IDE
	Individual Patient Expanded Access Applications: Form FDA 3926

                                                                                  Content current as of:
      01/04/2018Expanded Access

          
                        Information for Patients
          Information for Physicians
          Information for Industry
          How to Submit a Request (Forms)
          Keywords, Definitions, and Resources
          Submission Data
          Contact Information
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop